21-Year DPP Follow-Up: Life-style Intervention, However Not Metformin, Lowers Multimorbidity Danger in Prediabetes

An intensive life-style intervention was related to a decrease long-term burden of multimorbidity amongst adults with prediabetes, whereas metformin was not related to a statistically important discount vs. placebo, in line with a 21-year follow-up analysis of the Diabetes Prevention Program (DPP) revealed June 15 in JAMA.

The observational, multicenter cohort evaluation included 2021 morbidity information for 1,173 individuals from the DPP and DPP Outcomes Study (DPPOS) (68% ladies). Participants have been Medicare enrollees who have been at excessive danger for kind 2 diabetes at enrollment between 1996 and 1999 and had initially been randomized to intensive life-style intervention (n=385), metformin 850 mg twice every day (n=385) or placebo (n=403).

The intensive life-style intervention comprised 16 particular person core periods, adopted by two years of month-to-month upkeep periods. The intervention focused at the least 7% weight reduction through the first six months, with upkeep supported by dietary modification and at the least 150 minutes per week of moderate-intensity bodily exercise.

The randomized DPP intervention section had a imply period of three.2 years, and DPPOS follow-up has continued since 2002. Median participant age was 51 years at randomization and 74 years at 2021 consequence ascertainment.

During DPPOS, the placebo intervention was discontinued, metformin was provided open label to eligible individuals, and people initially assigned to life-style intervention attended twice-yearly booster periods.

At 21 years, multimorbidity – outlined as at the least two of 15 prespecified prevalent situations, together with hypertension, coronary heart failure, coronary artery illness/ischemic coronary heart illness, cardiac arrhythmias and hyperlipidemia – was current in 85% of the cohort: 82% of individuals assigned to life-style intervention, 85% assigned to metformin and 87% assigned to placebo. Three or extra situations have been current in 72% of individuals assigned to life-style intervention vs. 81% in each the metformin and placebo teams. The median variety of situations was 4 within the life-style intervention group and 5 within the metformin and placebo teams.

The most prevalent continual situations have been hyperlipidemia (76%), hypertension (75%) and diabetes (67%).
In covariate-adjusted analyses, task to life-style intervention was related to a decrease danger of multimorbidity vs. placebo (hazard ratio [HR], 0.79), whereas task to metformin was not related to a major discount vs. placebo (HR, 0.91). Results have been comparable when diabetes was excluded from the multimorbidity definition. The affiliation was stronger in an evaluation restricted to the highest-cost multimorbidity dyads, together with mixtures of stroke, continual obstructive pulmonary illness, continual kidney illness, coronary heart failure and bronchial asthma (HR for life-style vs. placebo, 0.57).

“Because lifestyle modification can be safe and cost-effective, sustaining those behaviors among Medicare beneficiaries at risk of diabetes may help to reduce health burden and health care spending,” write Marcel E. Salive, MD, and colleagues for the DPP Research Group.

“The lifestyle intervention strategies implemented in the [U.S.] DPP offer a practical and effective approach that may reduce the health care burden associated with aging,” write Hermes Florez, MD, PhD, MPH, MA; Caroline Foster, PhD; and Gilberto Vizcaino, MD, PhD, in an accompanying editorial comment. “Modest weight loss through healthy nutrition and increased physical activity remains a cornerstone to preserve quality of life and to potentially promote healthy longevity in this population.”